Fig. 3From: Investigating the potential of proton therapy for hypoxia-targeted dose escalation in non-small cell lung cancerMean DVHs for heart, lungs and esophagus are shown for the whole cohort (solid lines) for conventional non-escalated VMAT plans and dose-escalated proton plans. Color bands represent the cohort 25th to 75th percentile. Reductions in dose with dose-escalated proton plans are clearly visible for all OARs, despite the increased dose to the targetBack to article page